Stocks · Health care · Pharmaceutical Preparations

Stoke Therapeutics, Inc.

STOK Clue Score65

United States Fiscal year ends December CIK 0001623526 Results filed 29 Oct 2026

Add to watchlist

By person

9 insiders · 2 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Barry Ticho

Chief Medical Officer

—

$189.91K (2) scheduled

−$189.91K

11,864

0.0184%

$320.22K

+377.4%

Skorpios Trust entity

10% owner

—

3,906,181

6.05%

$105.43M

−56.1%

Adrian R. Krainer

Director

—

283,302

0.4390%

$7.65M

−30.0%

Edward M. MD Kaye

Director

—

124,557

0.1930%

$3.36M

+365.6%

Arthur Tzianabos

Director

—

31,339

0.0486%

$845.88K

−1.3%

Jonathan Allan

General Counsel & Corp Sec

—

20,598

0.0319%

$555.97K

+159.5%

Jason Hoitt

Chief Patient Officer

—

10,276

0.0159%

$277.36K

+157.7%

Thomas Leggett

Chief Financial Officer

—

10,172

0.0158%

$274.56K

—

Arthur A Levin

Director

—

4,237

0.0066%

$114.36K

—

Stoke Therapeutics, Inc.

What the insiders did Scheduled selling only

By person